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Abstract
Numerous models have been developed to address key elements in the biology of breast
cancer development and progression. No model is ideal, but the most useful are those that
reflect the natural history and histopathology of human disease, and allow for basic
investigations into underlying cellular and molecular mechanisms. We describe two types of
models: those that are directed toward early events in breast cancer development
(hyperplastic alveolar nodules [HAN] murine model, MCF10AT human xenograft model); and
those that seek to reflect the spectrum of metastatic disease (murine sister cell lines 67,
168, 4T07, 4T1). Collectively, these models provide cell lines that represent all of the
sequential stages of progression in breast disease, which can be modified to test the effect
of genetic changes.
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Introduction
The development of animal models for breast cancer
research covers a nearly 100-year span, starting with the
pioneering work of Little, and later that of Strong, Heston,
and Bittner, among others [1]. By selective inbreeding,
numerous mouse strains were produced, with characteris-
tic incidence frequencies and biologic characteristics of
‘spontaneous’ mammary tumors. Later, rat breast tumor
models, frequently involving exposure to chemical carcino-
gens, were added to the roster of available animal tools.
These rodent models were useful for testing hypotheses
regarding the etiology of breast cancer (genetic, viral, envi-
ronmental), for learning about factors that can play a role
in breast cancer progression (hormonal, immunological),
and for development of prevention and treatment strate-
gies. The arrival of the immunodeficient nude mouse
during the 1960s opened the door to the development of
xenograft models of human breast cancer. More recently
the transgenic and knockout technologies have yielded
mouse strains with specific genetic alternations or defi-
ciencies that result in breast cancer development.
All of these models have strengths and weaknesses.
Given the extensive population, genetic, and phenotypic
heterogeneity of human breast cancers, none of the
models can represent more than a very small fraction of
the possible avenues by which human breast cancers
develop, progress, or behave. The inbred mouse models
are ‘black boxes’, in which the relevant mechanisms that
underlie cancer development are highly complex and
largely unknown. The chemical carcinogen or virus-asso-
ciated models do not seem to mimic, at least superficially,
the etiology of human cancer. The transgenic models,
although mechanistically clearer than the others, often
sacrifice complexity and the tempo of natural history. Fur-
thermore, although they may show how gene alterationsBreast Cancer Research    Vol 2 No 5 Heppner et al
can effect cancer development, they do not necessarily
reflect how they do so under the ‘normal’ conditions of
maturation, endocrinologic change and environmental
exposures that occur during the long preclinical period
during which a woman passes from being at risk to devel-
oping breast cancer.
In our minds, the ‘ideal’ in vivo model would meet several
criteria. First, it would recapitulate the histopathologic spec-
trum and heterogeneity of breast neoplasia in women. It
would also reproduce the natural history of the disease in
terms of a prolonged and sporadic time span for develop-
ment, with the variability in course that is characteristic of
human cancer. In addition, it would lend itself to deciphering
and confirming the cellular and molecular events, and the
interactions among them, that are of relevance to human
disease. Finally, it would achieve all of these objectives at an
acceptable level of experimental convenience and cost.
With some trepidation, we describe two types of model
that, although certainly not ideal, have been designed to
address two distinct areas of breast cancer biology: pro-
gression of proliferative breast disease to frank neoplasia,
and metastasis of primary cancer to distant sites.
Preneoplastic models of breast cancer
development
Most studies of preneoplasia and early progression of
mammary tumors have utilized mouse HAN [2]. Medina [3]
described a number of HAN lines that progress to carci-
noma at different rates. When HAN tissue is transplanted
into epithelium-free mammary fat pads, the transplanted
epithelium expands to fill the mammary gland and resem-
bles the normal mammary gland epithelium of pregnant
mice. These HAN lines are not cultured cell lines, but
rather tissue must be transplanted serially. The preneo-
plastic stage may be maintained indefinitely by serial trans-
plantation but, if allowed to persist in situ, foci of
carcinoma arise and rapidly growing tumors develop.
Although the HAN models are the basis for much informa-
tion regarding the basic biology of mammary cancer, a
number of differences in the histology and biology of
mouse and human lesions exist. Unlike the HAN models, in
which homogeneous lobuloalveolar lesions consistently
give rise to rapidly growing adenocarcinomas within a few
months, the breasts of women who are at high risk for pro-
liferative breast disease are heterogeneous, and early
breast cancer grows slowly.
The MCF10AT system is a xenograft model of progressive
human proliferative breast disease. In this model the pro-
gression of a T24-Ha-ras-transformed derivative of normal-
appearing MCF10A cells [4] (ie MCF10AneoT [5]) can be
followed from a histologically precancerous stage to
development of frank invasive carcinoma [6]. In contrast to
MCF10A cells, MCF10AneoT cells form persistent lesions
in immunodeficient mice when 1×107 cells suspended in
Matrigel are inoculated subcutaneously [6]. MCF10AneoT
cells and lines derived by alternating in vivo transplanta-
tion and in vitro culture (MCF10ATn) are collectively
known as the MCF10AT system [7]. MCF10AT cells grow
in immunodeficient mice, in which, over a period of several
months, a percentage of lesions undergo a sequence of
progressive histologic changes. These changes mimic
those observed in the breasts of women who are at high
risk for breast cancer, and culminate in a significant pro-
portion of grafts with frankly invasive carcinoma. The
lesions formed by lines of the MCF10AT system are com-
posed of a heterogeneous spectrum of ductular tissues
with a range of morphology that includes mild hyperplasia,
moderate hyperplasia, atypical ductal hyperplasia (ADH),
carcinoma in situ, moderately differentiated and undiffer-
entiated carcinoma, and histologically normal ducts.
Although it may be argued that the presence of mutant
Ha-ras gene, a rare mutational event in human breast
cancers, may have contributed to the transformation
process by initiation and/or selection of a subpopulation of
MCF10A cells, the presence of mutant Ha-ras is clearly
not sufficient for histologic progression of MCF10AT cells.
Indeed, MCF10AneoT clones that express high levels of
protein encoded by mutant Ha-ras have been shown to
lack the ability to form lesions [8]. Furthermore, 50% of
human breast carcinomas express elevated levels of the
protein encoded by normal Ha-ras [9,10].
An important feature that distinguishes MCF10AT cells
from parental MCF10A cells is the presence of a func-
tional wild-type estrogen receptor (ER). MCF10AT cells
are able to respond to estrogen treatment in vitro with
increase in size and ability to form colonies on soft agar
[11,12] and in vivo with rapid morphological conversion to
ADH and ductal carcinoma in situ (DCIS) [13]. The
effects of estrogen on histologic progression to ADH and
DCIS appear to be ER-mediated, because treatment of
animals with tamoxifen causes specific suppression of
progression to ADH and DCIS [14]. Also, the highest
levels of ER in human breast tumors are generally
observed in atypia and nonhigh-grade DCIS [15].
Much like human breast cancers that have lengthy natural
histories, the lesions produced by premalignant MCF10AT
xenografts are slow growing and not yet committed to a
single pathway of cancer unless they are manipulated by
hormonal supplementation. Remarkable features of the
MCF10AT system are the reproducible generation of pre-
malignant lesions and the few cytogenetic alterations
present in the various MCF10AT generations that are not
already present in the parental MCF10A cells [4,6,16].
Establishment of tumorigenic variants of MCF10AT
xenografts has been difficult. However, serial trocar
passage of small pieces of MCF10AT lesions have yieldedhttp://breast-cancer-research.com/content/2/5/331
tumorigenic variants that produce heterogeneous tumors
with prominent areas of DCIS and invasive carcinoma.
One of the 14 clones derived from this variant repro-
ducibly generates tumors with predominant comedo DCIS
(MCF10DCIS.com) within a few weeks [17,18].
Breast cancer is a heterogeneous disease, and the het-
erogeneous spectrum of disease progression exhibited by
this model is indicative of its multipotentiality. The absence
of commitment to a single pathway of cancer, and its easy
manipulability by hormonal agents, render the MCF10AT
xenograft model the only currently available human model
that has been shown to exhibit the histologic stigmata
identified in women who are at high risk for developing
breast cancer, and furthermore to undergo preneoplastic
and neoplastic progression in vivo.
The invasive carcinomas generated by MCF10AT
xenografts are themselves heterogeneous. Different histo-
logic differentiation (squamous, glandular, and undifferen-
tiated) is seen, as well as distinctive immunohistochemical
staining for breast cancer-associated markers such as
erbB2, ER, cyclin D1, mucins, keratins, and p53. There-
fore, although the cancers that develop from this single
cell line derived from a single patient may represent only a
subset of human breast cancer, the model is not limited to
a single cancer phenotype.
Metastatic breast cancer models
Although there are a number of human breast cancer lines
that will metastasize in the xenograft setting, none fully
reflect the spectrum of metastatic disease in humans.
Numerous laboratories have been able to obtain subpopu-
lations from both rat and mouse mammary tumors that
differ in metastatic capacity [19–21]. Generally, these
models consist of paired subpopulations, one of which is
highly metastatic and the other not, but specific deficien-
cies of the nonmetastatic variants are usually unknown,
and so the mechanisms of metastatic failure are obscure.
The metastatic process is a sequence of steps (invasion,
intravasation, transport, arrest, extravasation, and growth)
that must be accomplished by cancer cells before distant
metastases are established. Nonmetastatic cell lines are
unable to complete one or more steps in the metastatic
cascade, whereas metastatic cell lines must be able to
complete all of them. In order to follow the sequential
spread and replication of tumor cells, a sensitive method
to determine the presence of clonogenic tumor cells in
host tissue is required. This can be accomplished by using
tumor cells that are resistant to specific drugs and cloni-
genic assays in drug-containing selective medium that
quickly kills host cells but not tumor cells.
Tumor subpopulation lines 67, 168, 66, and 410.4 were
isolated from a single, spontaneously arising mammary
tumor from a Balb/cfC3H mouse. Sublines 168FAR
(diaminopurine-resistant) and 66C14 (thioguanine-resis-
tant) were selected from the parental populations 168 and
66, respectively, and sublines 4T1 and 4T07 (both
thioguanine-resistant) were derived from the parental pop-
ulation 410.4. The geneticin-resistant subline 67NR was
obtained by transfection of line 67. These subpopulations
are phenotypically heterogeneous for a number of charac-
teristics but share a common origin. Subpopulations are
classified as metastatic on the basis of their ability to
metastasize spontaneously from the orthotopic site
[22,23]. One line, 4T1, metastasizes to the lung, liver,
bone, and brain via the hematogenous route, whereas
66c14 metastasizes to the lung and liver via the lymphat-
ics. Sublines 67, 168FAR and 4T07 are highly tumori-
genic, but fail to metastasize at different steps. The
nonmetastatic 67NR cells fail to leave the primary site;
168FAR cells reach the regional lymph nodes but fail to
produce nodules and do not advance past the nodes; and,
although 4T07 cells may be recovered from the blood and
lungs, visible metastases never develop. Thus, this com-
prehensive set of sublines offers the potential to correlate
specific genetic alterations with specific steps in the
metastatic process, as well as to test antimetastatic thera-
pies for their ability to interfere with known stages of the
process. The metastatic lines show a distribution similar to
that of human breast cancer. In addition, 4T1 is one of the
very few lines of any origin that spontaneously metasta-
sizes to bone.
Conclusion
We describe two nontransgenic, in vivo models for study-
ing breast cancer development. The models reflect two
stages of the disease as they are seen in women. The pre-
clinical MCF10AT model recapitulates the histologic spec-
trum of proliferative breast disease in women who are at
high risk for developing invasive cancer. The metastatic
model allows for investigation into mechanisms that are rel-
evant to the routes and distribution patterns seen in women
with systemic disease. We believe that models such as
these, which are centered on the biology of the disease,
can be used to guide research into the eventual eradication
of breast cancer as a significant medical problem.
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